FA+Ropivacaine
PreclinicalSmall molecule
FA+Ropivacaine is one of 20 small molecule programs targeting Postoperative Analgesia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Postoperative Analgesia
#DrugCompanyPhaseTrials
1Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Duragesic
CCephalon
Approved
Decadron
AAspen Global Incorporated
Approved
Nubain
AAultman Health Foundation
Approved
Celebrex
PPhiladelphia Eye Associates
Approved
EXPAREL
Pacira Pharmaceuticals, IncApproved
Intrathecal Morphine
Pacira Pharmaceuticals, IncPhase 3
Bupivacaine Only
Pacira Pharmaceuticals, IncPhase 3
Anrikefon
ZZhujiang Hospital
Phase 3
Fentanyl and Bupivacaine
HHospital Central Dr. Luis Ortega
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Postoperative Analgesia1 trial
Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy
Recruiting·—·N/A·NCT07209345·216 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FA+Ropivacaine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBeijing Tiantan Hospital